RecruitingPhase 4NCT06350955

IV Iron-induced Hypophosphatemia After RYGB

Intravenous Iron-induced Hypophosphatemia in Patients With Roux-en-Y Gastric Bypass: a Single-blind, Randomized Clinical Trial Comparing Iron Isomaltoside (Monofer®) and Ferric Carboxymaltose (Ferinject®)

Sponsor

Lucie Favre

Enrollment

94 participants

Start Date

May 2, 2024

Study Type

INTERVENTIONAL

Conditions

Roux-en-Y gastric bypass Hypophosphatemia

Summary

The primary objective of the study is to compare the incidence of hypophosphatemia in RYGB patients treated with intravenous (IV) single dose of iron isomaltoside (Monofer®) or ferric carboxymaltose (Ferinject®).

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Iron Carboxymaltose and a drug called Iron isomaltoside for people with hypophosphatemia and roux-en-y gastric bypass. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.